Literature DB >> 2926024

The effects of background illumination and stimulant medication on smooth pursuit eye movements of hyperactive children.

F W Bylsma1, R T Pivik.   

Abstract

Problems with visual information processing have been reported in children with the diagnosis of attention deficit disorder with hyperactivity (ADD H), and deficits in oculomotor control have been posited as an important factor in this phenomenon. To assess aspects of oculomotor performance, smooth pursuit eye movements (PEMs) were recorded electrooculographically in 20 ADD H and 20 age-matched control children and computer-analyzed for discrete (velocity arrests) and global (root mean square error) disruptions. The effects of stimulant medication (methylphenidate), together with manipulations designed to influence behavioral (attention) and physiological (cerebellar) processes involved in PEM performance, were examined. The tracking patterns of nonmedicated ADD H children contained significantly more discrete aberrations on baseline conditions. Although no single experimental manipulation significantly improved tracking performance in ADD H children, combining all experimental conditions did normalize PEMs in these subjects. Slight improvements in PEM performance in association with medication correlated positively with dose of medication and with medication-related improvements in behavior. In light of these data, arguments are presented in support of (a) hypoarousal as a contributing factor underlying oculomotor difficulties in ADD H children, and (b) subcortical involvement in PEM dysfunction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2926024     DOI: 10.1007/BF00910771

Source DB:  PubMed          Journal:  J Abnorm Child Psychol        ISSN: 0091-0627


  22 in total

1.  Smooth pursuit eye movements, attention, and schizophrenia.

Authors:  P S Holzman; D L Levy; L R Proctor
Journal:  Arch Gen Psychiatry       Date:  1976-12

2.  Single-dose effects of amphetamine on smooth pursuit eye movements in man.

Authors:  V Filip; I David; M Filipová
Journal:  Act Nerv Super (Praha)       Date:  1978-12

Review 3.  The biochemical basis of minimal brain dysfunction.

Authors:  S E Shaywitz; D J Cohen; B A Shaywitz
Journal:  J Pediatr       Date:  1978-02       Impact factor: 4.406

4.  Eye-tracking performance in psychiatric patients.

Authors:  C Shagass; M Amadeo; D A Overton
Journal:  Biol Psychiatry       Date:  1974-12       Impact factor: 13.382

5.  Normative data on revised Conners Parent and Teacher Rating Scales.

Authors:  C H Goyette; C K Conners; R F Ulrich
Journal:  J Abnorm Child Psychol       Date:  1978-06

6.  Smooth pursuit eye movements and attention in psychiatric patients.

Authors:  R T Pivik
Journal:  Biol Psychiatry       Date:  1979-12       Impact factor: 13.382

7.  Vestibular suppression in peripheral and central vestibular disorders.

Authors:  J D Hood; S Korres
Journal:  Brain       Date:  1979-12       Impact factor: 13.501

Review 8.  Frontal lobe dysfunctions in schizophrenia--I. Eye movement impairments.

Authors:  S Levin
Journal:  J Psychiatr Res       Date:  1984       Impact factor: 4.791

9.  Area-luminance relationship for a constant light peak of the standing potential in the human eye.

Authors:  E Dodt; M Baier
Journal:  Ophthalmologica       Date:  1984       Impact factor: 3.250

10.  Influence of peripheral vision upon vestibulo-ocular reflex suppression.

Authors:  J D Hood; E Waniewski
Journal:  J Neurol Sci       Date:  1984-01       Impact factor: 3.181

View more
  2 in total

Review 1.  Pharmacological treatment effects on eye movement control.

Authors:  James L Reilly; Rebekka Lencer; Jeffrey R Bishop; Sarah Keedy; John A Sweeney
Journal:  Brain Cogn       Date:  2008-12       Impact factor: 2.310

2.  Effect of a visual tracking intervention on attention and behavior of children with Attention Deficit Hyperactivity Disorder.

Authors:  Shiva Janmohammadi; Hojjat Allah Haghgoo; Mojgan Farahbod; Paul G Overton; Ebrahim Pishyareh
Journal:  J Eye Mov Res       Date:  2020-04-22       Impact factor: 0.957

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.